What role does the WHO's International Agency for Research on Cancer play in shaping global public health policy? Discuss with reference to recent drug reclassifications.

The International Agency for Research on Cancer (IARC), WHO's specialised cancer agency at Lyon, evaluates agents for carcinogenicity through its Monographs Programme and sorts them into Group 1 to Group 3 [1]. Its February 2026 reclassification of three widely prescribed medicines shows both the reach and the limits of its policy influence.

Functions in global health governance

• Evidence synthesis authority: international working groups of independent scientists pool epidemiological, animal-bioassay and mechanistic evidence — Volume 137 was evaluated by scientists convened at Lyon in November 2024 [1].
• Norm-setting for regulators: IARC does not license or ban drugs; national regulators, insurers and courts use its classifications as the evidentiary base for labelling, screening and litigation.
• Agenda-setting: a Group 1 listing pushes a hazard onto national research and surveillance priorities.

The recent drug reclassification

• Hydrochlorothiazide (antihypertensive), voriconazole (antifungal) and tacrolimus (transplant immunosuppressant) were placed in Group 1 — carcinogenic to humans [1].
• Hydrochlorothiazide is linked to squamous cell and other skin carcinomas; voriconazole acts through a phototoxic mechanism in transplant patients; tacrolimus to non-Hodgkin lymphoma [1].
• All three sit on the WHO Model List of Essential Medicines, so millions of patients are affected [2].

Limits and communication challenge

• IARC performs hazard identification — whether an agent can cause cancer — not risk assessment of probability at a given dose [3]. Conflating the two invites panic-driven treatment discontinuation.
• Follow-through rests with domestic systems: India's CDSCO and the Pharmacovigilance Programme of India must translate the finding into labelling, monitoring and physician advisories [4].
• Higher sun-exposure populations need targeted counselling rather than blanket withdrawal.

IARC thus functions as global public health's evidence backbone — authoritative in classification, dependent on states for action. India's response should pair updated prescribing guidance and dermatological screening for at-risk patients with clear risk communication, converting an international hazard alert into calibrated domestic protection consistent with the right to health under Article 21 and SDG-3.